Irinotecan sucrosofate
As of the edition of 20 October 2026, Irinotecan sucrosofate is a drug: stopped in 2018; acts on TOP1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2018
- Kind
- Unknown
- Registered trials
- 20, 1 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Pregnancy and women's health; Urinary and reproductive; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TOP1 | DNA topoisomerase 1 | P11387 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 8 | 7 | 0 | 0 |
| Phase 2 | 10 | 7 | 1 | 1 |
| Phase 3 | 2 | 1 | 1 | 0 |
| All trials | 20 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| PharmaEngine | Lead sponsor of trials | 2006 to now |
| Merrimack Pharmaceuticals | Lead sponsor of trials | 2011 to now |
| Sumitomo Pharma | Lead sponsor of trials | 2014 to now |